Vascular endothelial growth factor C as a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 7, 2011, Pages 319-324

  Chen, Shuo Chueh ^a,b   Shih, Chuen Ming ^a   Tseng, Guan Chin ^a   Cheng, Wei Erh ^a   Chiou, Jean ^b   Hsiao, Michael ^c   Kuo, Min Liang ^d   Su, Jen Liang ^b,e   Chen, Chih Yi ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

Early recurrence; Stage I NSCLC; Survival; VEGF C

Indexed keywords

VASCULOTROPIN C;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 80051519867     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chen G, Liu X, Wang Z, Liu FY. Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg 2010;37:546-51.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
3. Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, et al. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol 2008;31:22-8.
4. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA Methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28.
5. Lee HJ, Jo J, Son DS, Lee J, Choi YS, Kim K, et al. Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection. J Korean Med Sci 2009;24:824-30.
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
7. Strauss GMH, Maddaus JE, Johnstone MA. Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006;24(suppl):7007.
8. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82.
9. Ayabe T, Tomita M, Matsuzaki Y, Ninomiya H, Hara M, Shimizu T, et al. Micrometastasis and expression of nm23 messenger RNA of lymph nodes from lung cancer and the postoperative clinical outcome. Ann Thorac Cardiovasc Surg 2004;10:152-9.
10. Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009;115:1701-12.
11. Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 2008;44:1057-67.
12. Ito H, Oshita F, Kameda Y, Suzuki R, Ikehara M, Arai H, et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep 2002;9:119-23.
13. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003;97:457-64.
14. Martini. N, Melamed MR. Multiple primary lung cancers. J of Thorac. Cardiovas. Surg 1975;70:606-611.
15. Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg 2002;235:133-9.
16. Noda E, Maeda K, Inoue T, Nishihara T, Nishiguchi Y, Ohira M, et al. Predictive value of vascular endothelial growth factor-C expression for local recurrence of rectal carcinoma. Oncol Rep 2007;17:1327-31.
17. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003;97:457-64.
18. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001;85:255-60.
19. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000;119:804-13.
20. Carter D, Vazquez M, Flieder DB, Brambilla E, Gazdar A, Noguchi M, et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer 2007;56:193-9.
21. Rice D, Kim HW, Sabichi A, Lippman S, Lee JJ, Williams B, et al. The risk of second primary tumors after resection of Stage I nonsmall cell lung cancer. Ann Thorac Surg 2003;76:1001-7;discussion 1007-8.